NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.31 by $0.80. The biopharmaceutical company had revenue of $294.45 million for the quarter, compared to analyst estimates of $12 million. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. Lexicon Pharmaceuticals's revenue for the quarter was up 4124.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.26) EPS. View Lexicon Pharmaceuticals' Earnings History.

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Lexicon Pharmaceuticals.

6 brokers have issued twelve-month price targets for Lexicon Pharmaceuticals' stock. Their forecasts range from $3.00 to $17.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 43.7% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lexicon Pharmaceuticals.

Headlines about LXRX stock have trended somewhat negative on Monday, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 12,570,000 shares, an increase of 13.1% from the September 30th total of 11,110,000 shares. Based on an average daily volume of 2,040,000 shares, the days-to-cover ratio is presently 6.2 days. Currently, 12.3% of the shares of the stock are sold short. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), Orexigen Therapeutics (OREX), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), MannKind (MNKD), Iovance Biotherapeutics (IOVA) and RYB Education (RYB).

Lexicon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.15%), State Street Corp (0.90%), Pictet Asset Management Ltd. (0.69%), Point72 Asset Management L.P. (0.50%), Wedbush Securities Inc. (0.38%) and Russell Investments Group Ltd. (0.06%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

LXRX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Wedbush Securities Inc., Russell Investments Group Ltd., Pictet Asset Management Ltd., Millennium Management LLC, State Street Corp and Commonwealth Equity Services LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $4.87.

Lexicon Pharmaceuticals has a market capitalization of $517.53 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals.

The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com/.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.